Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genelux Corp. (GNLX)
NASDAQ:GNLX
Holding GNLX?
Track your performance easily
GNLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.60 - $16.60
Previous Close$2.93
Volume77.44K
Average Volume (3M)154.00K
Market Cap
$100.50M
Enterprise Value$69.07M
Total Cash (Recent Filing)$33.64M
Total Debt (Recent Filing)$2.21M
Price to Earnings (P/E)―
Beta-0.74
Next Earnings
Nov 12, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding34,535,471
10 Day Avg. Volume128,832
30 Day Avg. Volume154,001
Standard Deviation0.47
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)2.69
Price to Sales (P/S)12562.28
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.63K
Enterprise Value/Gross Profit406.29
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$16.67Price Target Upside468.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Genelux Corp. News
PremiumCompany Announcements
Genelux Corp. Releases New Corporate Presentation
PremiumCompany Announcements
Genelux Corp Unveils Forward-Looking Corporate PresentationBulls Say, Bears Say
Bulls Say
Efficacy In Ovarian CancerThe prior Phase 2 program for Olvi-Vec in platinum-resistant/refractory ovarian cancer demonstrated 54% response rates with progression-free survival of 11 months compared to historical rates of 15%-20% response and progression-free survival of 5 months.
Innovative Cancer TreatmentOlvi-Vec uses a triple mode of action by directly killing cancer cells, inducing a tumor-specific immune response, and generating durable anti-cancer memory.
Strategic Partnerships And FundingGenelux partner Newsoara, an emerging biotech company in China, is responsible for funding the Phase 2 trial of Olvi-Vec in recurrent non-small cell lung cancer in the U.S.
Bears Say
Market InterestOncolytic viruses have historically seen limited clinical and commercial success, leading to waning investor interest over the years.
Operational UpdatesThe company did not provide an update on the status of the Phase 2 study initiation, which was previously guided to start in 2Q24.
Stock PerformanceGNLX shares have dropped to a near 52-week low due to a lack of significant catalysts and challenging markets for microcap biotech.
---
Ownership Overview
12.31% Insiders
3.53% Mutual Funds
5.25% Other Institutional Investors
75.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.60 and its highest was $16.60 in the past 12 months.
What is Genelux Corp.’s market cap?
Currently, no data Available
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Aug 14, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.208 by -$0.012.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -$0.2.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 34,535,473 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.208. Following the earnings report the stock price went up 1.914%.
Which hedge fund is a major shareholder of Genelux Corp.?
Among the largest hedge funds holding Genelux Corp.’s share is Highbridge Capital Management LLC. It holds Genelux Corp.’s shares valued at 1M.
---
Genelux Corp. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (468.94% Upside)
$16.67 (468.94% Upside)
Blogger Sentiment
Bullish
GNLX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.40%
12-Months-Change
Fundamentals
Return on Equity
-88.57%
Trailing 12-Months
Asset Growth
44.05%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
---
GNLX Stock 12 Month Forecast
Average Price Target
$16.67
▲(468.94% Upside)
Technical Analysis
TRACON Pharmaceuticals
―
Bioxcel Therapeutics
―
Adaptimmune Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering GNLX
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-44.12%
reiterated a buy rating 5 months ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -44.12% per trade.
---